A16z-Backed Biotech Braveheart Seeks $318.8 Million in US IPO
Braveheart Bio Inc., a clinical-stage biopharmaceutical company backed by Andreessen Horowitz (a16z), is planning to go public with an IPO targeting $318.8 million in fundraising. This move reflects continued investor confidence in the biotech sector and adds to the growing number of biotech companies entering the public markets.
1 Article
Trace's outlet lean is shown first — tap Left / Center / Right on each source to add your rating too.
- BloombergTrace: Center
A16z-Backed Biotech Braveheart Seeks $318.8 Million in US IPO
Braveheart Bio Inc., a clinical-stage biopharmaceutical company backed by Andreessen Horowitz (a16z), is planning to go public with an IPO targeting $318.8 million in fundraising. This move reflects continued investor confidence in the biotech sector and adds to the growing number of biotech companies entering the public markets.
Rate outletRead original
Readers say
How does this story lean?
Outlet ratings above are Trace's curated source map. Vote here (same as on the home feed) — one vote per browser, changeable anytime. Rate individual outlets in the coverage list below.
Comments
0No comments yet. Say what you noticed in the coverage.
Trending